Recombinant quadrivalent HPV vaccine (Serum Institute of India)

重组四价人乳头瘤病毒疫苗

Report date: 2022/01/14 13:23:58

Base Information

Drug NameRecombinant quadrivalent HPV vaccine (Serum Institute of India)
Drug Alias NameTetravalent HPV vaccineqHPV vaccineHuman papillomavirus (types 6, 11, 16, 18) L1 VLP vaccineHuman papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccineHuman papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine
ClassificationVaccines > Development/production technology > Genetically engineered subunit vaccineVaccines > Application > Prophylactic vaccineVaccines > Vaccine type > Multivalent vaccine +[4] 
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsPapillomavirus InfectionsHIV InfectionsSexually Transmitted Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesPuerto Rico
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesSerum Institute Of India Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSerum Institute Of India Ltd
Inactive CompaniesNational Institute Of Allergy And Infectious Diseases (Niaid)
Active IndicationsPapillomavirus Infections
Inactive IndicationsHIV InfectionsSexually Transmitted Diseases

Other Information

ATC CodeN/A
Related LinksN/A